US 8598219

I'll search for authoritative information on US 8598219, including recent CAFC docket activity.

Let me check for any current CAFC 2026 appellate docket activity involving this patent and its PTAB history.

Let me check the current USPTO fee/status and any 2026 Federal Circuit activity specifically tied to this patent.

US Patent 8,598,219 — Analyst Summary

Source of record: USPTO/Google Patents full text (fetched 2026-09-27): https://patents.google.com/patent/US8598219/en; FreePatentsOnline.com/8598219.html. The patent number is confirmed literally as 8,598,219 (application 13/901,437); I did not substitute any similar number.

Bibliographic data

Caveat on inventor names: The Google Patents/FreePatentsOnline inventor list ("Alberto Macciocchi") differs from the USPTO assignment records captured on the same page, which name "Macciocchi, Giulio" and "Macciocchi, Simone." I am reporting both literally; I cannot reconcile which is authoritative without the face of the printed patent.

Abstract (verbatim)

"The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments."

Technology / specification context

The patent discloses shelf-stable liquid palonosetron (a 5-HT₃ antagonist) formulations, addressing the poor shelf life of the prior-art injectable of US 5,202,333 (pH 3.7). Key teachings:

• Palonosetron free-base concentration broadly 0.01–5 mg/mL; optimal ~0.05 mg/mL.
• pH 4.0–6.0, optimally 5.0 (Example 1 shows pH 5.0 is most stable).
• Citrate buffer ~10–100 mM and/or EDTA ~0.005–1.0 mg/mL.
• Mannitol (with a chelating agent) improves stability; 41.5 mg/mL (4.15%) is isotonic and such low mannitol acts as a tonicifier, not a sweetener (which would require >100 mg/mL).
• Representative IV formulation (Example 4): palonosetron HCl 0.05 mg/mL, mannitol 41.5 mg/mL, EDTA 0.5 mg/mL, trisodium citrate 3.7 mg/mL, citric acid 1.56 mg/mL, pH 5.0 ± 0.5.
• Supports single-use vials of 5 mL (≈0.25 mg), terminal sterilization, and room-temperature storage claims.

Claims

The patent has 8 claims; two are independent — claim 1 and claim 8.

Claim 1 (independent) — plain language: A single-use, unit-dose IV formulation for a human, to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, consisting of a 5 mL sterile aqueous isotonic solution containing:

• palonosetron hydrochloride, 0.25 mg (measured as free base),
• EDTA at 0.005–1.0 mg/mL, and
• mannitol at 10–80 mg/mL,
• and the formulation must be stable for 24 months at room temperature.

Claims 2–7 (dependent on claim 1):

• Claim 2: EDTA is 0.5 mg/mL.
• Claim 3: mannitol is 41.5 mg/mL.
• Claim 4: solution further comprises a citrate buffer.
• Claim 5: citrate buffer is 20 mM.
• Claim 6: solution is buffered at pH 5.0 ± 0.5.
• Claim 7: combination of claims 2, 3, 5, 6 — EDTA 0.5 mg/mL + mannitol 41.5 mg/mL + 20 mM citrate buffer + pH 5.0 ± 0.5.

Claim 8 (independent) — plain language: Identical to claim 1 but the stability limitation is 18 months at room temperature instead of 24 months.

Litigation / validity history (relevant to scope)

• Hatch-Waxman: The '219 patent was asserted in multiple ANDA suits (e.g., D.N.J., including Helsinn v. Dr. Reddy's, No. 3:11-cv-03962; D. Del. cases). FDA records confirm Aloxi-related suits referencing patent 8598219.
• Post-Grant Review: PGR2014-00010, filed 2014-09-02 by Accord Healthcare, Inc. against the '219 patent — one of the first-ever PGRs. Per Greenb/PTAB reporting, institution was denied (2014-11-24). This is consistent with the fact that the '219 patent's claims were treated as eligible for PGR (AIA/FITF patent).
• Federal Circuit / Supreme Court: Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., Fed. Cir. No. 16-1284, 855 F.3d 1356 (May 1, 2017), aff'd, 586 U.S. ___ (No. 17-1229, Jan. 22, 2019). The Court (Thomas, J., unanimous) held a sale to a third party obligated to keep the invention confidential can still place it "on sale" under AIA §102(a)(1). This invalidated the asserted '219 (and related) claims. I note the CAFC opinion reportedly refers to the patent as the '219 patent and describes it as covering "a fixed dose of 0.25 mg of palonosetron in a 5 mL solution."

Note on the docket instruction: I searched for 2026 CAFC dockets specifically for 8,598,219 and found none. The only appellate/Supreme Court activity I can confirm for this patent is the 2017 CAFC decision and 2019 Supreme Court affirmance above. Any suggestion of a 2026 Federal Circuit docket for this number is not supported by the search results I retrieved, so I flag this as an area of uncertainty rather than assert it.

Status discrepancies I observed (reported literally, not reconciled)

Different sources give slightly different status characterizations for the same number:

• Google Patents: "Expired – Fee Related", anticipated expiration 2024-01-30.
• One aggregator (GreyB/Pharsight) listed a "Maintenance Fee Reminder Mailed" on 2025-07-21 and an "Expire Patent" entry dated 2026-01-05 for US8598219.
• FreePatentsOnline notes "8518981 … 7960424 … 7947725 … 7947724" as related family members.

I cannot authoritatively confirm the 2025/2026 fee-status entries from primary USPTO sources based on the searches performed, so treat those two dates as unverified.

Bottom line

US 8,598,219 is a Helsinn/Roche palonosetron formulation patent (original assignees Helsinn Healthcare SA and Roche Palo Alto LLC), filed 2013-05-23 as application 13/901,437, issued 2013-12-03, with a 2003-01-30 priority claim. It claims a 5 mL isotonic single-use IV solution of 0.25 mg palonosetron (free base) with EDTA and mannitol, asserted as stable 24 months (claim 1) or 18 months (claim 8) at room temperature, plus dependent citrate/pH refinements. It is now expired (anticipated 2024-01-30), was challenged in PGR2014-00010 (institution denied), and was the central patent in the Helsinn v. Teva on-sale-bar litigation that reached the Supreme Court in 2019.

I'll research the litigation history for US patent 8,598,219 by querying multiple litigation and patent sources.

Let me search for the specific district court cases and PTAB proceedings listed for this patent.

Let me search for the remaining district court cases and the Federal Circuit appeal docket.

Litigation Involving U.S. Patent No. 8,598,219

Scope note: I searched specifically for the literal number 8,598,219. Every case below is tied to that number either because the '219 patent was directly asserted/at issue, or because it was consolidated into a Helsinn "Aloxi®" (palonosetron) case that expressly named the '219 patent. Where a docket number is listed on the patent's own Google Patents litigation record but the party names/outcome are not recoverable from that record, I say so rather than guess. I did not substitute related numbers such as 8,598,218, 8,518,981, 8,729,094, 7,947,724, 7,947,725, or 7,960,424 — but I flag where those sibling patents appear alongside '219 in the same suits.

1. The central case — D.N.J. Hatch-Waxman litigation and its appeals

Sources: Google Patents litigation record (https://patents.google.com/patent/[US8598219](/patent/US8598219)/en); D.N.J. opinions (https://www.bipc.com/assets/PDFs/Insights/Opinion-Intellectual_Property-Helsinn_Healthcare_v_Teva_Pharmaceuticals_USA-20160303.pdf; https://www.finnegan.com/a/web/56530/.../20151113_311cv03962_helsinn_v_teva_di360_memorandum_opinionpd.pdf); Fed. Cir./SCOTUS opinions (https://www.supremecourt.gov/opinions/18pdf/586us1r10_fcgk.pdf).

Related consolidated/companion D.N.J. cases (Helsinn family):

• Helsinn v. Dr. Reddy's Labs., Ltd. et al., No. 3:12-cv-02867 (filed May 11, 2012) — companion 505(b)(2)/NDA case (predominantly the '724 "chelating agent" issue). Consolidated/related.
• No. 3:11-cv-05579 and No. 3:13-cv-05815 — consolidated into 11-3962 (13-5815 concerned the '981 patent).
• No. 2:14-cv-04274 — D.N.J. action in which the court denied Helsinn's motion for a preliminary injunction to stop Teva's March 23, 2018 at-risk launch (cited in the Sagent brief as D.I. 89, Jan. 30, 2018).

2. Sagent Pharmaceuticals litigation (D.N.J.) — '219 expressly asserted

Source: https://storage.courtlistener.com/recap/gov.uscourts.njd.[351305](/patent/351305)/gov.uscourts.njd.351305.71.0.pdf (Sagent's supplemental brief, which identifies the Asserted Patents as '724, '725, '424, '219, and '094).

3. Delaware Hatch-Waxman litigation (D. Del.) — '219 asserted

The '219 patent was named as an asserted patent in the D. Del. Aloxi® actions below. Confirmed from the consolidated Stipulation and Order (D. Del. C.A. No. 13-688-GMS) and FDA/court records:

Source for the stipulation naming '219: https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.56.0.pdf. Source for the Dec. 27, 2013 filing date: FDA NDA 203-050 review memo (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203050Orig1s000OtherR.pdf).

Caveat: The stipulation (Sept. 2014) shows the parties agreed to remove with prejudice the '218 and '981 claims while adding the later-issued '094 patent, so the precise '219 claim status in the individual Delaware dockets is not fully reconstructed here.

4. Additional docket numbers listed on the patent's own litigation record (parties not recoverable from that record)

Google Patents lists the following as litigation involving US 8,598,219. I report them literally; the record supplies the court and number but not the defendant names, so I cannot confirm plaintiffs/defendants or outcomes for each:

D. Del. (Delaware): 1:15-cv-00264 (terminated 2018-09-11; identified elsewhere as involving Hospira Inc.), 1:15-cv-00265 (terminated 2015-12-03), 1:15-cv-00865, 1:18-cv-01674.

D.N.J. (New Jersey): 3:15-cv-01228; 3:15-cv-02077 (duplicate entry 2:15-cv-02077); 3:15-cv-02078; 3:15-cv-07015; 3:15-cv-08132; 2:16-cv-04239; 3:16-cv-00681 (Sagent — see above); 3:16-cv-00173 (Sagent — see above); 2:17-cv-03216 (duplicate entry 3:17-cv-03216); 3:13-cv-05815.

(Note: the "2:"/"3:" prefix pairs are the same cases listed twice under different New Jersey docket conventions in the source data.)

Source: https://patents.google.com/patent/US8598219/en (litigation section).

5. PTAB — Post-Grant Review

Discrepancy flagged: Google Patents annotates PGR2014-00010 as "(Settlement)", whereas the PatentDocs PGR report, DrugPatentWatch, and the PGR statistics literature all indicate the petition was not instituted (decision date 11-24-2014). I cannot reconcile the "Settlement" label from primary sources; treat the "institution denied" characterization as the better-supported one, but note it as a source conflict.

Sources: https://patentdocs.org/2014/09/11/pgr-report-the-attack-of-35-usc-112/; https://www.drugpatentwatch.com/p/alphasignals/litigation/drugname/index.php?query=PALONOSETRON+HYDROCHLORIDE; https://natlawreview.com/article/pto-litigation-center-report-september-3-2014.

6. Appellate / Supreme Court dockets for '219

Bottom line

Litigation involving US 8,598,219 is extensive but now closed. The patent was asserted primarily against generic palonosetron ANDA/505(b)(2) filers (Teva, Dr. Reddy's, Sandoz, Sagent, Aurobindo, Bedford/Ben Venue, Accord, Cipla, Hospira, and others), in the District of New Jersey and the District of Delaware. Its validity was ultimately dispositive-in-reverse: the Federal Circuit in Helsinn v. Teva (No. 16-1284) held the '219 claims invalid under the AIA on-sale bar, and the Supreme Court affirmed in No. 17-1229 (2019). PTAB PGR2014-00010 (Accord) was filed but not instituted. The patent is expired and all identified district-court actions are terminated or were settled/dismissed.

No litigation involving patent number 8,598,219 was found that post-dates the 2019 Supreme Court decision (consistent with the earlier analysis, I again found no 2026 CAFC or new district-court docket for this specific number).

Sources of record:

• https://patents.google.com/patent/US8598219/en (litigation links/dockets)
• https://www.drugpatentwatch.com/p/alphasignals/litigation/drugname/index.php?query=PALONOSETRON+HYDROCHLORIDE
• https://storage.courtlistener.com/recap/gov.uscourts.njd.351305/gov.uscourts.njd.351305.71.0.pdf
• https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.56.0.pdf
• https://www.supremecourt.gov/opinions/18pdf/586us1r10_fcgk.pdf
• https://patentdocs.org/2014/09/11/pgr-report-the-attack-of-35-usc-112/
• https://www.eisai.com/news/pdf/enews201577pdf.pdf and https://www.eisai.com/news/pdf/enews201720pdf.pdf

I'll start by reconciling a direct conflict in my source materials: the structured "PTAB proceedings on file" block says there are no AIA trials for this patent, while the earlier-generated sections describe PGR2014-00010. Let me verify with live sources before writing.

Confirmed a significant discrepancy. Let me run a few more checks: any IPRs on the '219, and the related family PGRs (PGR2016-00007/8) for context.

Proceedings overview

Total AIA trial proceedings on US 8,598,219: one (1). A single Post-Grant Review, PGR2014-00010 (Accord Healthcare, Inc. v. Helsinn Healthcare S.A.), filed 2014-09-02 and terminated by settlement on 2014-11-24 at the preliminary stage — before any institution decision and with no Final Written Decision. No IPRs, no CBMs, no FWDs, and no Federal Circuit appeals of any PTAB decision on this patent. Bottom line for a defendant today: there is no PTAB-driven invalidation to point to and no PTAB estoppel against anyone — but that is largely academic, because the '219 patent expired on 2024-01-30 and its asserted claims were held invalid under the AIA on-sale bar in Helsinn v. Teva (Fed. Cir. 2017, aff'd 2019). The PTAB record on this patent is thin; the fatal blow came from the district court/appellate on-sale ruling, not from the Board.

⚠️ Direct contradiction flagged. The structured "PTAB proceedings on file" block in my task inputs states the USPTO ODP API "returns no AIA trial proceedings for this patent." That is contradicted by the primary record: PGR2014-00010 is a real, well-documented AIA post-grant review on the '219 patent, with a public Board judgment dated 2014-11-24. I have gone with the primary documents, not the structured block. The likely explanation is an ODP-indexing gap for a pre-institution PGR terminated by settlement, but I cannot verify that; I flag it rather than paper over it.

⚠️ Second contradiction flagged (against the earlier-generated sections). The "Litigation summary" above attributes PGR2014-00010 to "Unified Patents, LLC." That is wrong. The Board's own caption reads "ACCORD HEALTHCARE, INC., Petitioner, v. HELSINN HEALTHCARE S.A. and ROCHE PALO ALTO LLC, Patent Owner." The "Unified Patents" attribution appears to have propagated from the "Unified Patents Litigation Data" licensing label on the Google Patents page. The earlier section's characterization of the outcome as "institution denied" is also imprecise — the Board never reached institution; it terminated on a joint motion to terminate based on settlement.

PGR2014-00010 — Accord Healthcare, Inc. v. Helsinn Healthcare S.A. and Roche Palo Alto LLC

• Type: Post-Grant Review (AIA; patent eligible for PGR as a post-March 16, 2013 continuation-in-part — application 13/901,437)
• Filed: 2014-09-02 (within the nine-month PGR window; the '219 issued 2013-12-03)
• Status: Aggregators list "Institution Denied"; the primary Board document is a "Judgment — Termination of the Proceeding, 37 C.F.R. §§ 42.72–42.73" dated 2014-11-24. Plain-English gloss: the Board granted the parties' joint motion to terminate the proceeding on settlement and did not render a final decision. "[W]e determine that it is appropriate to enter judgment and terminate the proceeding without rendering a final decision."
• Judge panel: Lora M. Green, Sheridan K. Snedden, and Jon B. Tornquist, Administrative Patent Judges
• Counsel: Petitioner — Michael J. Fink (Greenblum & Bernstein). Patent Owner — Eric W. Dittmann and Naveen Modi (Paul Hastings), Thomas L. Irving (Finnegan), Mark E. Waddell (Loeb)
• Petition grounds: Challenged claims 1–5 and 8 (both independents, 1 and 8, plus dependents 2–5). All grounds were § 112 — the petition raised no § 102 or § 103 art (which is the whole point of a PGR):
  • § 112(a) written description — stability: the specification allegedly did not show possession of a formulation stable at 18 or 24 months at room temperature; it had only "general statements" and examples running "beyond a couple of weeks" at best. Support: Declaration of Arnold J. Repta, Ph.D. (Ex. 1015).
  • § 112(a) enablement — pH: the claims recite no pH limitation, yet the specification's sole relevant formulation was pH 5.0 ± 0.5 and the inventors' own Bonadeo Declaration allegedly stated that mannitol/EDTA formulations "required" pH 4–6.
  • § 112(b) — "regards as the invention": the claims allegedly omitted the inventors' own regarded inventive pH range.
  • § 112(a) written description — pH range (Gentry Gallery line): the omitted pH range was allegedly an essential/critical feature.
• Institution decision: None — never reached. The petition was filed 2014-09-02; a Patent Owner Preliminary Response was not yet due when the parties filed a joint motion to terminate (Paper 7) and the written settlement agreement (Ex. 2001) on 2014-11-20. The Board emphasized the "preliminary stage of the current proceeding." Petitioner then requested a fee refund on 2014-11-25; the Board approved the refund 2014-12-15 — another tell that this never became an instituted trial.
• Final Written Decision: None issued. No claim was canceled or sustained; every claim of the '219 patent remained (and legally remains) as issued by the PTAB's lights.
• Settlement / termination: Terminated 2014-11-24 by judgment on the parties' joint motion. The parties represented that, "[a]side from this post-grant review proceeding, the '219 patent is not the subject of any other proceedings currently before the Office," and identified several ongoing district-court litigations involving the '219. The settlement agreement itself is confidential — the Board granted the joint request under 35 U.S.C. § 327(b) and 37 C.F.R. § 42.74(c) to treat it as business confidential and keep it separate from the '219 file. Terms are not public.
• Appeal: None. A settlement-terminated PGR produces no appealable FWD. (The Helsinn v. Teva appeals — Fed. Cir. No. 16-1284, 855 F.3d 1356 (2017); Supreme Court No. 17-1229, 139 S. Ct. 628 (2019) — arose from D.N.J. 11-3962, not from any PTAB proceeding.)
• Defensive value: Low direct value today, for two reasons. First, because the review ended pre-institution on settlement, there is no § 325(e) estoppel and no claim-level PTAB holding — a defendant cannot say "claim 1 is dead at the Board." Second, the '219 patent is expired (anticipated 2024-01-30), so assertion risk is historical. Its real significance is evidentiary/strategic: it shows two things a challenger should reuse — (i) the § 112 written-description attack on the "stable at 18/24 months at room temperature" limitation and (ii) the on-sale-bar theory, both of which the family later validated elsewhere (see below). Also note that this was only the second-ever PGR filed (patentdocs, 2014-09-11), and Accord's settlement was followed by a sealed consent judgment in the parallel Delaware case — consistent with the family-wide "sue-and-settle" posture.

Primary source: Board Judgment (Paper 10), 2014-11-24 — https://www.docketalarm.com/cases/PTAB/PGR2014-00010/Post_Grant_Review_of_U.S._Pat._8598219/docs/11-24-2014-Board/Final_Decision-10-Judgment___Termination_of_the_Proceeding_37_CFR_4272_4273.pdf (also docketed at USPTO PTAB; the petition and Repta declaration (Ex. 1015) are public). Petition summary: patentdocs, "PGR Report — The Attack of 35 U.S.C. § 112," 2014-09-11 — https://patentdocs.org/2014/09/11/pgr-report-the-attack-of-35-usc-112/

Family context (adjacent PTAB proceedings — NOT against the '219 patent)

These involve the '219's own continuation, U.S. 9,173,942 ('942), and are useful only as signal; do not cite them as claim-level outcomes for the '219:

• PGR2016-00007 and PGR2016-00008 — Dr. Reddy's Laboratories v. Helsinn Healthcare S.A. (both filed 2016-02-05; both denied institution 2016-08-17; panel Toni R. Scheiner, Lora M. Green, Jacqueline Wright Bonilla). PGR2016-00008 challenged claims 1–19 of the '942 patent on § 112(a) written description and the AIA § 102(a)(1) on-sale bar (Helsinn–MGI Supply and Purchase Agreement). The Board denied institution, holding the AIA on-sale bar requires that the sale make the claimed invention available to the public — i.e., it adopted the narrow reading. That reading was later rejected by the Federal Circuit in Helsinn (2017) and the Supreme Court (2019), which held a confidential sale can still trigger the bar. DRL then withdrew its request for rehearing (2016-10-XX). Sources: https://www.docketalarm.com/cases/PTAB/PGR2016-00008/Post_Grant_Review_of_U.S._Pat._9173942/docs/08-17-2016-Board/Decision_Denying_Institution-11-Decision___Denying_Institution_of_Post_Grant_Review.pdf and https://www.docketalarm.com/cases/PTAB/PGR2016-00007/Post_Grant_Review_of_U.S._Pat._9173942/docs/08-17-2016-Board/Decision_Denying_Institution-12-Decision___Denying_Institution_of_Post_Grant_Review.pdf (also discussed in Buchanan, "4 PTAB Lessons on Scope of On-Sale Prior Art," 2017-01-26).
• IPR2015-xxxxx petitions by Dr. Reddy's against the '094 patent (attorney dockets REDDY 7.1R-010/012/013) exist in the same campaign family. I have not confirmed any IPR or PGR against the '219 patent itself beyond PGR2014-00010, and I decline to invent proceeding numbers for them.

Strategic summary

Claim-level status of the '219. At the PTAB, nothing was canceled and nothing was sustained — no claim of 8,598,219 was ever adjudicated on the merits in an AIA trial. Claims 1–8 remain as issued in the PTAB record because PGR2014-00010 died on settlement pre-institution. This is the single most important — and most easily overstated — point. A demand letter that says "the PTAB invalidated claim 1" would be flatly false. What did kill the asserted claims was judicial, not administrative: the Federal Circuit held the '219 (and '724/'725/'424) claims invalid under the AIA on-sale bar (855 F.3d 1356, 2017-05-01), and the Supreme Court affirmed (139 S. Ct. 628, 2019-01-22). So the accurate statement is: "Claims 1–8 were never tested at the Board; they were invalidated in district court/appeal on § 102(a)(1)." The '219 also expired 2024-01-30.

Estoppel landscape. Because no PGR was instituted and no FWD issued, § 325(e) estoppel never attached — not to Accord, not to its privies, not to anyone. (Estoppel under §§ 315(e)/325(e) is triggered by an instituted proceeding terminating in a FWD, not by a pre-institution settlement.) Practically, this means no prior-art ground is foreclosed by the PTAB, and any party facing (hypothetical) assertion could still run IPR/PGR/§ 282 defenses — though the patent's expiration makes that mostly theoretical. Note the two-way lesson: the '942 PGR shows the Board briefly embraced a narrow on-sale bar (public-sale-only) that the courts later reversed; if a similar PGR were run today, the Helsinn/Supreme Court reading would help a petitioner, not a patent owner.

Pattern signals. (i) Different petitioners, not one serial filer: Accord filed the '219 PGR; Dr. Reddy's filed the '942 PGRs — a coordinated-but-separate generic defense, not a single-petitioner campaign. (ii) No defensive aggregator: there is no Unified Patents or similar filing on the '219 record; the earlier attribution to Unified Patents was an error. (iii) Patent owner rarely litigated at the Board: Helsinn's only Board exposures on this family were met with settlement ('219) or successful institution denials ('942), and no PTAB decision on any palonosetron-family patent was appealed to the Federal Circuit; all the appellate energy was in the district-court track. (iv) Sue-and-settle posture: PGR termination (2014-11-24), the parallel Delaware consent judgment (2014-11-20), and the Sandoz/DRL/Sagent resolutions all point to systematic settlement rather than merits adjudication at the PTAB.

Recommended next steps

• If you are a defendant and want the paper trail: use the Board's own words, not aggregator labels. Quote the 2014-11-24 Judgment: the Board terminated "without rendering a final decision," at the "preliminary stage," on the parties' joint motion to terminate under 37 C.F.R. §§ 42.72–42.73, with the settlement kept confidential under 35 U.S.C. § 327(b). Cite the public PDF (link above). Do not describe this as an "institution denial" on the merits and do not attribute it to Unified Patents.
• Do not build any theory on PTAB claim cancellation — there is none. If you need invalidity leverage, cite Fed. Cir. 855 F.3d 1356 (2017) and U.S. 17-1229, 139 S. Ct. 628 (2019); for the '219 specifically the on-sale bar disposed of claims 1, 2, and 6 on appeal (asserted set at trial: claims 1, 2, 6, 7).
• If you are evaluating a live demand: check expiration first. Anticipated expiration 2024-01-30 (Orange Book pediatric exclusivity to 2024-07-30 per the earlier-generated section — treat as the earlier section's characterization, and reconcile against current USPTO fee/expiry status, which shows conflicting 2025/2026 reminders; I cannot verify those dates from primary sources here). An expired patent cannot be infringed prospectively, which moots most of the PTAB analysis.
• No active proceedings to track. There are no pending AIA trials on the '219 patent and no PTAB appeal docket; there is therefore no institution-deadline, oral-hearing, or FWD-due milestone to monitor. If your task inputs' structured block still asserts "no PTAB activity," treat it as incomplete rather than exculpatory — PGR2014-00010 is real and is the one entry that belongs in that field.
• Verification gap I could not close: I could not retrieve the live PTAB E2E / PTAB Center page for PGR2014-00010 in this session (the aggregated docket mirrors and the Board document itself were retrievable). If you need E2E-verified document-level confirmation, a direct PTAB Center pull on PGR2014-00010 and a dossier pull on PGR2016-00007/00008 would close it.

I'll research the assignment chain and ownership record for US 8,598,219.

Let me dig for the specific reel/frame numbers and correspondent data.

Let me try to pin down the individual reel/frame numbers.

I've hit the tool-call ceiling for this session. Below is the ownership reconstruction based on the records I was able to retrieve, with clear flags on what I could and could not verify.

Verification caveat up front: I was able to retrieve the event list of the assignment chain (via the Google Patents legal‑events record, which is populated from the underlying USPTO assignment records), but I could not open the USPTO Assignment Center detail view for this patent in this session. Consequently I have one confirmed reel/frame (047534/0024) and could not retrieve the reel/frame or the correspondent‑of‑record for the other entries. I am not going to invent them. Where a field is unknown I say so.

Inventors

Per the patent's own face (Google Patents / FreePatentsOnline) the named inventors are eight people. Their recorded assignments sort cleanly into two employer groups, which is the single most important structural fact about this chain:

Pattern note (non‑sinister): this is the classic joint‑invention / split‑employer fact pattern — the five Helsinn employees assign to Helsinn Healthcare SA and the three Roche‑side inventors assign to Roche Palo Alto LLC, on the same day (2013‑05‑23). That explains the two parallel 2013 assignments and Roche's co‑ownership of the issued patent. It is not a "all inventors departed within 12 months" signal.

Two discrepancies I must flag literally (do not auto‑correct):

1. Inventor‑name mismatch. The patent face/Google Patents lists "Alberto Macciocchi." The assignment record captured on the same page names "Macciocchi, Giulio" and "Macciocchi, Simone" — two different given names, not one. The litigation transcripts refer repeatedly to Dr. Alberto Macciocchi, a Helsinn employee. I cannot reconcile the assignment‑record names against the patent face without the printed assignment documents, so I report both literally.
2. PGR petitioner contradiction vs. the earlier section. The previously generated litigation summary attributed PGR2014‑00010 to "Unified Patents, LLC" as petitioner (relying on the Google Patents line "Petitioner: 'Unified Patents PTAB Data'"). The GreyB/IPVerse PTAB record shows the petitioner was Accord Healthcare, Inc., respondent Helsinn Healthcare S.A., institution denied 2014‑11‑24. The "Unified Patents" string on the Google Patents page is the data‑source attribution, not the petitioner. The earlier section should be corrected.

Original assignee

Helsinn Healthcare S.A. (Lugano, Switzerland) and Roche Palo Alto LLC, as co‑owners on the issued patent.

• Did they ship a product embodying the claims? Yes. The claims cover the ALOXI® (palonosetron HCl) 0.25 mg/5 mL IV presentation — the commercial product of Helsinn. The D.N.J. court found the '219 claims valid and infringed by Teva's 0.25 mg ANDA product and expressly tied Example 4 of the specification to the Aloxi formulation. Aloxi is (per FDA) the reference listed drug under NDA 021372, marketed in the U.S. by Eisai under license. Helsinn also listed the '219 patent in the Orange Book (expiry 2024‑01‑30, pediatric 2024‑07‑30).
• Helsinn's line of business: family‑owned, family‑run Swiss pharma; an in‑licensing/development/out‑licensing ("business‑to‑business") model; owner of a finished‑dose plant in Ireland (Helsinn Birex Pharmaceuticals Ltd) and an API plant in Biasca, Switzerland. Currently operating.
• Roche Palo Alto LLC: U.S. subsidiary/affiliate within the Roche group (successor to Syntex (U.S.A.) Inc., which discovered palonosetron). Currently operating as part of Roche.
• Status: neither assignor is dissolved or in bankruptcy on the records I reviewed. Note, however, the 2022 secured‑financing pledge to Hamilton SA LLC (below) — a financing event, not an insolvency.

Assignment timeline

The chain (per Google Patents legal events for US 8,598,219, which mirror the USPTO assignment records). Dates are as stated on the record; I could not separately distinguish execution date from recording date, so treat them as the recorded dates.

• 2013‑05‑23 — Reel/frame not retrievable in this session

  • Conveyance: Assignment ("Assignment of Assignors' Interest")
  • Assignors: Calderari, Giorgio; Bonadeo, Daniele; Cannella, Roberta; Panuccio, Carmine; Macciocchi, Giulio; Macciocchi, Simone (note: assignment names two Macciocchis not on the patent face)
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable — not exposed by the sources I could reach
  • Context: employment/inventor assignment at filing — the Helsinn‑employed inventors.

• 2013‑05‑23 — Reel/frame not retrievable in this session

  • Conveyance: Assignment ("Assignment of Assignors' Interest")
  • Assignors: Malefyt, Thomas; Miksztal, Andrew; Lee, Kathleen M.
  • Assignee: Roche Palo Alto LLC
  • Correspondent: not retrievable
  • Context: employment/inventor assignment at filing — the Roche‑side inventors. (Confirms Roche's co‑ownership.)

• 2013‑05‑23 — Application filed by Helsinn Healthcare SA and Roche Palo Alto LLC (app. 13/901,437, continuation‑in‑part of 13/087,012). (Filing event, not an assignment.)

• 2016‑05‑11 — Reel/frame not retrievable in this session

  • Conveyance: Assignment (transfer of Roche's undivided interest)
  • Assignor: Roche Palo Alto LLC
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable
  • Context: internal/strategic consolidation — Roche exits the co‑ownership; Helsinn becomes sole owner. This is the pivot from two‑company co‑ownership to single‑company ownership, ~2.5 years post‑issuance and after the 2015 trial judgment.

• 2018‑11‑14 — Reel 047534 / Frame 0024 ✅ (confirmed)

  • Conveyance: Patent Co‑Ownership Agreement
  • Assignor: Helsinn Healthcare SA
  • Assignees: Helsinn Advanced Synthesis SA; Helsinn Therapeutics (U.S.), Inc.; Helsinn Birex Pharmaceuticals Ltd.
  • Correspondent: not retrieved (document image would carry it)
  • Context: intra‑group reorganisation — the single operating parent re‑titles the patent into co‑ownership with three of its own operating subsidiaries (API manufacturing; U.S. commercial entity; Irish finished‑dose plant).

• 2018‑11‑21 — Reel/frame not separately retrieved, but expressly filed as a correction of Reel 047534 / Frame 0024

  • Conveyance: Corrective Assignment ("Corrective Assignment to correct the spelling of assignee name Helsinn Birex Pharmaceuticals Ltd.; addresses of assignees previously recorded on Reel 047534 Frame 0024")
  • Assignor: Helsinn Healthcare SA
  • Assignees: Helsinn Birex Pharmaceuticals, Ltd.; Helsinn Therapeutics (U.S.), Inc.; Helsinn Advanced Synthesis SA
  • Correspondent: not retrieved — but the record itself establishes that the same filing agent handled both the 2018‑11‑14 recording and its 7‑day‑later correction, i.e. a single transaction and its clean‑up, not two transfers.
  • Context: correction of the immediately preceding record (spelling/address fix). Same‑transaction bookkeeping.

• 2022‑12‑30 — Reel/frame not retrievable in this session

  • Conveyance: Security Interest ("Security Interest (see document for details)")
  • Assignors/Joint Debtors: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
  • Assignee/Secured Party: Hamilton SA LLC
  • Correspondent: not retrieved
  • Context: securitization / collateral pledge — a blanket security interest granted over the group's IP by the Helsinn debtors to a secured party. Not a transfer of title.

• 2023‑09‑20 — Reel/frame not retrievable in this session

  • Conveyance: Release by Secured Party
  • Assignor/Secured Party: Hamilton SA LLC
  • Assignees/Debtors released: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrieved
  • Context: release of the 2022 security interest — the pledge was extinguished; title never left the Helsinn group. (Consistent with a refinanced/repaid facility.)

• 2024‑01‑30 — Anticipated expiration (legal‑status event, not an assignment).

Bottom line on the record: the Assignment Center does have records for this patent — a genuine chain of eight recorded events — but I could only confirm one reel/frame (047534/0024) and could not retrieve a single correspondent‑of‑record. Full reel/frame + correspondent capture would require opening each assignment's detail view / document image in the USPTO Assignment Center.

Timeline diagram

timeline
    title Ownership of US 8598219
    2013 : Helsinn inventors assign to Helsinn Healthcare
         : Roche inventors assign to Roche Palo Alto
         : Patent issues Dec 3
         : Accord Intas suit filed Dec 27
    2016 : Roche Palo Alto assigns to Helsinn
    2018 : Co-ownership deal among Helsinn affiliates
         : Corrective assignment one week later
    2022 : Security interest to Hamilton SA
    2023 : Security interest released
    2024 : Patent expires Jan 30

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only post‑issuance transfers of title are to Helsinn Advanced Synthesis SA, Helsinn Therapeutics (U.S.), Inc., and Helsinn Birex Pharmaceuticals Ltd. (Reel 047534/0024, 2018‑11‑14). None carries an "IP / Patents / Licensing / Holdings / Ventures" suffix; each is an operating subsidiary of the same family‑owned group (API manufacturing, U.S. commercial arm, Irish finished‑dose plant). No single‑member Delaware/Texas LLC, no registered‑agent address. Roche Palo Alto LLC is a Big‑Pharma affiliate, not a shell.

2. Known asserter in the chain — NOT PRESENT.
No assignee in the chain matches Acacia, Marathon, IV, IPNav, Wi‑LAN, Conversant/Mosaid, Vringo, Pendrell, Round Rock, or any Spangenberg entity. The 2022 encumbrance holder Hamilton SA LLC is a secured party / collateral agent, not a plaintiff — and its interest was released 2023‑09‑20. No Unified Patents/RPX NPE‑plaintiff listing applies to any Helsinn entity here.

3. Repeat correspondent across the chain — UNCLEAR.
I could not retrieve a correspondent name for any entry, so I cannot make the recurrence finding. The only verifiable same‑firm signal is structural: the 2018‑11‑21 corrective assignment expressly corrects Reel 047534/Frame 0024, proving one recording agent handled the 2018‑11‑14 record and its correction. That is routine transactional clean‑up, not an NPE signature.

4. Cascading transfers — NOT PRESENT.
The two closest‑in‑time records (2018‑11‑14 and 2018‑11‑21) are a filing and its correction, seven days apart, same assignor, same transaction — not arms‑length transfers. There is no chain of unrelated LLCs in under 24 months; the only multi‑year gap (2016 → 2018 → 2022) tracks corporate housekeeping and financing.

5. Pre‑litigation transfer — NOT PRESENT (and the surface timing is misleading).
The two 2013‑05‑23 assignments precede the Accord/Intas suit filed 2013‑12‑27 asserting the '219 patent, i.e. within ~7 months. But the assignors are the inventors assigning to their employers (Helsinn and Roche) — the ordinary at‑filing employment assignment, not a transfer arranged to enable assertion, set venue, or create standing. No NPE‑side acquisition precedes any suit.

6. Bankruptcy fire‑sale — NOT PRESENT.
No Chapter 7/11 by any Helsinn entity appears in the records. The 2022‑12‑30 security interest in favor of Hamilton SA LLC is a consensual collateral pledge, and it was released 2023‑09‑20 — a refinancing/repayment event, not a distressed sale.

7. Privateering — NOT PRESENT.
Helsinn asserted the patents in its own name, joined by co‑owner Roche Palo Alto LLC, directly against ANDA filers (Dr. Reddy's, Sandoz, Teva, Accord/Intas, Hospira, Sagent). There is no NPE proxy asserting on Helsinn's behalf; the patent owner is the plaintiff.

8. Defensive aggregator — NOT PRESENT.
The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates in the Helsinn operating group (with the 2022 pledge released in 2023), and the patent expired 2024‑01‑30.

Verdict

Operating-company assertion.

The record shows an inventor‑to‑employer at‑filing assignment split between the two co‑owners (both 2013‑05‑23), then a 2016‑05‑11 consolidation of Roche's interest into Helsinn Healthcare SA, then intra‑group co‑ownership housekeeping among Helsinn's own operating subsidiaries (Reel 047534/0024, corrected 2018‑11‑21), then a 2022‑12‑30 collateral pledge to Hamilton SA LLC that was released 2023‑09‑20. Every party in the chain is a pharmaceutical operating company or a lender; the patent owner asserted the claims itself against generic competitors; the product (Aloxi 0.25 mg/5 mL) embodies the claims. No shell entity, no NPE assignee, no fire‑sale, no defensive aggregator.

Verification link: https://assignmentcenter.uspto.gov/ (search patent number 8598219); the indexed mirror is https://assignment.uspto.gov/patent/index.html. To complete the reel/frame + correspondent capture I flagged as missing, open each of the eight records' detail/document images there — the correspondent field is not exposed in the aggregated legal‑events view I could reach.

I'll supplement the prior-art analysis with targeted searches on the key cited references, since the full text gives me citations but I want to verify dates, assignees, and content before mapping to claims.

I have strong results on the key references. Let me verify a few remaining cited references that could be relevant to the formulation limitations (buffers, chelating agents, tonicity agents, and the "setrones" reference).

Prior Art Analysis — U.S. Patent No. 8,598,219 ("the '219 patent")

Grounded in: the authoritative full text at https://patents.google.com/patent/[US8598219](/patent/US8598219)/en (fetched 2026-09-27) and the searches run this session. This builds on the earlier summary/litigation sections; where I have a new observation that qualifies them, I flag it.

0. Analytical framework (read before the tables)

Effective prior-art date. The '219 record lists prior-art date 2003-01-30 (provisional US 60/444,351 and PCT/EP2004/000888). Because the claims were filed as a continuation-in-part (the record shows 13/901,437 as a CIP of 13/087,012), the true §102 date for any new-matter claim element could be later — but the record as published treats 2003-01-30 as the critical date, and I use it literally. This is a genuine caveat, not a footnote: CIP status is exactly the kind of thing that shifts a §102(b) bar.

Applying that date pre‑AIA:

• §102(b): references published more than one year before 2003-01-30, i.e., before 2002-01-30.
• §102(a): references published before 2003-01-30 but within the one-year grace window.
• §102(e): U.S. patents/publications (and English-language PCT publications designating the U.S.) with a filing date before the applicant's date — the standard ground for the 2000–2003 references.

Critical structural point for anticipation. Every claim of the '219 patent — independent claims 1 and 8 and all dependents 2–7 — requires all of: (a) palonosetron (0.25 mg free base / 5 mL in claim 1), (b) EDTA 0.005–1.0 mg/mL, and (c) mannitol 10–80 mg/mL, plus the room-temperature stability limitation. Anticipation under §102 requires a single reference disclosing every element, arranged as claimed. No cited patent reference does this. The cited art is therefore predominantly obviousness art (§103), and I say so explicitly rather than force an anticipation label. I map each reference to the claim(s) it touches and label the §102 category honestly.

1. The closest prior art — palonosetron-specific references

1.1 US 5,202,333 A — the single most relevant reference

• Title: Tricyclic 5-HT₃ receptor antagonists
• Assignee/inventors: Syntex (U.S.A.) Inc. (later Roche Palo Alto LLC); Clark, Berger, Eglen, Smith, Weinhardt
• Filing/priority: 1989-11-28 (app. 07/704,565 filed 1991-05-21) • Issued: 1993-04-13
• §102 category: §102(b) statutory bar (published ~10 years pre-critical date).
• Disclosure/conversion: Discloses and claims the palonosetron compound (Formula I, R³ = 1-azabicyclo[2.2.2]oct-3-yl), states these compounds "are useful in the prevention and treatment of emesis" (incl. chemotherapy/radiotherapy-induced), teaches parenteral (IV) administration in "single unit dosage form," and gives a "representative" IV formulation in Example 13: palonosetron HCl 10–100 mg; dextrose monohydrate (isotonic); citric acid monohydrate 1.05 mg; sodium hydroxide 0.18 mg; water to 1.0 mL — reported pH 3.7. It also teaches a broad concentration range of 0.000001 %w–10 %w (≈0.01–100 mg/mL).
• Anticipation? No for '219 claims 1–8. It discloses the active, the indication, the IV route, and a concentration window — but not EDTA, not mannitol, not the 0.25 mg/5 mL unit dose, and (per the '219 specification itself) the Example 13 formulation is the unstable pH-3.7 antecedent with "<1–2 year" shelf life. It anticipates only the genus (a palonosetron IV formulation), which is not what claims 1–8 recite.
• Actual role: It is the starting reference for the obviousness attacks litigated in the ALOXI® cases and in PGR2014-00010-era papers; the '219 patent itself distinguishes it, which is why the district court / Federal Circuit "on-sale" fight (not §103) is what decided validity. See the patent text (Example 13 table) and the D.N.J. record quote at https://storage.courtlistener.com/recap/gov.uscourts.njd.[261662](/patent/261662).178.0.pdf.

1.2 WO 2004/045615 A1 — palonosetron dosing (same applicant)

• Title: Palonosetron for the treatment of chemotherapy-induced emesis
• Applicant: Helsinn Healthcare SA • Filed: 2002-11-15 • Published: 2004-06-03
• §102 category: §102(e) (English-language PCT designating the U.S., filed before 2003-01-30).
• Disclosure: Claims methods of treating acute and delayed emesis with palonosetron and expressly identifies the 0.25 mg dose as "a particularly effective and versatile dose," for single or successive-day administration. It is a method-of-use / dosing document, not a formulation document.
• Anticipation? No. It does not disclose EDTA or mannitol in a palonosetron solution, nor the 5 mL isotonic unit dose composition. It overlaps claims 1/8 only on the "0.25 mg palonosetron / reduce CINV likelihood" concepts — but methods of treatment are not the formulation claims. Note the same-applicant/common-ownership issue under pre-AIA §103(c) would need checking.
• Source: https://patents.google.com/patent/WO2004045615A1/

1.3 WO 2004/067005 A1 — the '219's own PCT parent (NOT prior art)

• Title: Liquid pharmaceutical formulations of palonosetron • Applicant: Helsinn • Priority: 2003-01-30 • Published: 2004-08-12
• This is the international counterpart of the '219 family; it is the same invention, not §102 art. It should be treated as the family's priority document, not a reference. (Listed in the record because Google Patents echoes the family.)

1.4 WO 2004/073714 A1 — PONV use (NOT prior art)

• Title: Use of palonosetron treating post-operative nausea and vomiting • Applicant: Helsinn • Filed: 2003-02-18 • Published: 2004-09-02.
• Filed after 2003-01-30, so it is not §102 prior art against the '219 claims.

1.5 Helsinn family members listed as "citations" — same specification

• US 7,947,724 B2; US 7,947,725 B2; US 8,518,981 B2 (and US 8,598,218 / 8,598,219 siblings, US 7,960,424 B2). All share the '219 specification and 2003-01-30 priority. They are not prior art against the '219 patent — they are the same invention in different claim dress. (For completeness the record also lists US 5,510,486 and US 5,202,303 in the specification text and related-family "Family Cites Families" — note US 5,202,303 vs US 5,202,333 are different numbers in the record and should not be conflated.)

2. Other 5-HT₃-antagonist ("setron") patents — obviousness art on the excipients/pH

These teach that other setrons were marketed/claimed as buffered, isotonicized, chelator-containing IV solutions — the §103 template the '219 patent had to distinguish.

Anticipation view: None anticipates claims 1–8 — none discloses palonosetron, and none discloses the mannitol+EDTA combination in a palonosetron unit dose. Their value is §103: they establish that setron IV solutions were routinely buffered to mildly acidic pH and made isotonic with a tonicity agent, and that chelators were standard.

2.1 The granisetron multidose-vial pair (closely on-point for the excipient template)

• US 6,294,548 B1 — Multidose vial formulations for granisetron HCl • Hoffmann-La Roche • filed 1998-05-04 / issued 2001-09-25 • §102(b). Discloses granisetron HCl aqueous injection in unit vials, a citrate buffer to control pH (target 6, limits 5–7), tonicifying/isotonic solutions, autoclaving to sterilize, and stability over a pH 2–7 window. This is a strong "buffered, terminally-sterilized setron IV solution" teaching.
• US 2001/0020029 A1 — New multidose vial formulations for granisetron HCl • SmithKline Beecham • filed 1998-05-04 / published 2001-09-06 • §102(b). Companion disclosure.
• Anticipation? No (different drug; no mannitol-in-palonosetron, no 0.25 mg/5 mL). §103 relevance to claims 1, 4–8: teaches that a setron injection is stabilized by citrate buffer + isotonicity agent and heat-sterilized.
• Source: https://patents.google.com/patent/[US6294548B1](/patent/US6294548B1)/en

3. General formulation-technology patents — §103 support for the individual elements

Anticipation view: None anticipates. These are cited for the formulation toolbox (buffers, tonicifiers, chelators, preservatives, sterilization), i.e., §103.

4. Post-2003 / non-qualifying references in the citation list

(The record also lists "Cited By" items — US 9,066,980 B2 and US 8,598,218-family / US 9,308,266 B2, and third-party families such as TWI355936B and EP 4 019 023 A1 — none of which are backward prior art; they are later documents.)

5. Element-by-element §102 test for claims 1–8 (the decisive point)

Conclusion: On the face of the '219 citation list, no single patent reference anticipates any of claims 1–8. The patent's own specification admits the §102(b) '333 reference discloses a palonosetron IV formulation (pH 3.7) that failed the 1–2-year stability requirement — i.e., the patent distinguishes the closest art rather than being anticipated by it. Every cited reference is best characterized as §103 (obviousness) art, with the §112 written-description/enablement attack (lack of support for the 18/24-month stability limitation) raised separately in PGR2014-00010 (petition text: https://patentdocs.typepad.com/files/[303859](/patent/303859).pdf).

6. The prior art that actually invalidated the '219 patent (flagged, though not a "patent citation")

For completeness — and because it is the operative prior art — the '219's asserted claims were held invalid under §102(a)(1) on-sale/public-use, not §102 patent art:

• MGI Pharma License Agreement and Supply & Purchase Agreement (both dated 2001-04-06, publicly announced and filed in SEC Form 8-K, 2001-04-25) covering the 0.25 mg and 0.75 mg palonosetron products.
• Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), aff'd, 586 U.S. ___ (No. 17-1229, Jan. 22, 2019) — a confidential third-party sale can be "on sale."
• Sources: https://www.supremecourt.gov/opinions/18pdf/17-1229_2co3.pdf ; https://www.acc.com/sites/default/files/2019-08/Know%20Your%20IP%20-%20Supplemental%20Materials%20-%20August%[202019](/patent/202019).pdf

This is not in the "Patent Citations" table, so I list it separately rather than force it into the patent-reference mapping — but it is the single most outcome-determinative prior art for this number.

7. Ranked "most relevant prior art" (top tier)

1. US 5,202,333 A (Syntex, 1993-04-13) — palonosetron + emesis + IV formulation (Example 13, pH 3.7). §102(b). Closest art; anticipates the genus but not claims 1–8. Bears on all claims via §103.
2. US 6,294,548 B1 (Roche, 2001-09-25) and US 2001/0020029 A1 (SmithKline Beecham, 2001-09-06) — buffered, isotonic, terminally-sterilized setron IV vials. §102(b). §103 template for claims 1, 4–8.
3. WO 2004/045615 A1 (Helsinn, pub. 2004-06-03) — 0.25 mg palonosetron dosing for CINV. §102(e). Touches the dose element of claims 1/8.
4. US 5,854,270 A / US 5,955,488 A / US 6,063,802 A (Glaxo Wellcome, 1998–2000) — ondansetron liquid, freeze-dried and oral compositions. §102(b). §103 art on stabilized setron liquids.
5. General formulation art — US 5,272,137 (McNeil), US 6,132,758 (Schering), US 6,287,592 (Boots), US 2,003,009,5926 (Dugger) — vehicle/tonicity/stabilization teachings; §103.

8. Caveats I am obligated to state

• No anticipation found. I could not identify, within the '219 patent's own citation list, a single reference that discloses all elements of claims 1–8. Any assertion that a cited patent anticipates the '219 claims would require a reference I have not seen in this record. The genuine validity attack was the on-sale bar (Section 6) and a §112 written-description theory (PGR2014-00010).
• CIP date risk. Because 13/901,437 is a continuation-in-part, the §102 date could differ from 2003-01-30 for new matter; I used the published date literally.
• Reference-number discrepancy, reported not corrected: the specification text names "US 5,922,749," while the citation table prints "US5922749A." I did not auto-correct either.
• Inventor-name discrepancy (carried from the earlier section): Google Patents lists "Alberto Macciocchi"; assignment records on the same page name "Macciocchi, Giulio/Simone." Unreconciled.
• No 2026 CAFC activity for 8,598,219 was located this session (consistent with the earlier section); the operative appellate rulings remain the 2017 CAFC decision and the 2019 Supreme Court affirmance.

I'll ground the § 103 analysis in the actual prior-art record and the litigation findings before writing. Let me verify a few key references and how obviousness was treated.

Obviousness Analysis of U.S. Patent 8,598,219 under 35 U.S.C. § 103

Scope note (building on prior sections). This section assumes the claim set, family structure, and litigation history already established above. Two of those findings frame everything that follows: (1) the asserted claims of the '219 were held valid (non‑obvious and adequately described) by the District of New Jersey on 2015‑11‑13, and were then declared invalid under the AIA on‑sale bar by the Federal Circuit (855 F.3d 1356, 2017) and the Supreme Court (139 S. Ct. 628, 2019) — so the § 103 question was never finally resolved on appeal; and (2) the PTAB's only proceeding against this patent, PGR2014‑00010, raised only § 112 grounds — no § 102 or § 103 art at all (and terminated pre‑institution on settlement). Accordingly, the patent's only substantive § 103 engagement was at the district court, where the obviousness theory lost. The analysis below reconstructs the strongest combinations of record and explains both why a POSITA would have been motivated to combine, and why the fact‑finder nonetheless rejected them. Because the patent expired 2024‑01‑30, this is retrospective.

1. Legal framework and the critical date

• Governing statute. The '219 issued from application 13/901,437 (filed 2013‑05‑23), a CIP of 13/087,012. Because it contains post‑March‑16‑2013 matter, it is an AIA patent (which is why it was PGR‑eligible). As the earlier sections noted, the district court and parties nonetheless treated published prior art under pre‑AIA § 102(b), agreeing the operative date for published art was January 30, 2002 — one year before the 2003‑01‑30 priority date — while the on‑sale analysis proceeded under AIA § 102(a)(1). (D.N.J. op., n.61.) I flag this mixed posture: for a clean § 103 analysis the effective filing date and the applicable § 102/§ 103 regime should be fixed first, and the record is internally inconsistent on that point.
• Graham factors (Graham v. John Deere, 383 U.S. 1 (1966)): scope/content of the prior art; differences between the prior art and the claims; level of ordinary skill; and secondary considerations.
• Obviousness standard (KSR Int'l v. Teleflex, 550 U.S. 398 (2007)): a claimed combination is obvious where the elements were known, the combination was "according to known methods," and the results were "predictable"; also recognized are simple substitution of a known element, use of a known technique to improve similar devices, and "obvious to try" where there is "a finite number of identified, predictable solutions."
• Level of ordinary skill. The court treated the POSITA as a formulation scientist (Ph.D. or equivalent) with experience developing small‑volume parenterals — a person comfortable with tonicifiers, buffers, chelating agents, pH/stability profiling, and terminal sterilization.

2. The elements that must be found (or supplied by the POSITA's ordinary creativity)

Claim 1 (and claim 8, which differs only in the stated stability period) requires, in elemental form:

Dependents add: EDTA 0.5 mg/mL (2); mannitol 41.5 mg/mL (3); citrate buffer (4); 20 mM citrate (5); pH 5.0 ± 0.5 (6); and the combination (7).

Two claim‑construction facts materially affect the analysis and should be carried forward:

• The court construed the '219 preamble ("for intravenous administration to a human to reduce the likelihood of … CINV") as limiting, and identified the pertinent limitations as "reduce … cancer chemotherapy‑induced nausea and vomiting," "0.25 mg dose in 5 mL … solution," and "EDTA." (D.N.J. op..)
• In the later Cipla matter, a party successfully proposed (as a prosecution‑statement‑driven construction) that "said formulation is stable at 24[18] months when stored at room temperature" means the formulation has a pH of 4.0–6.0 enabling that stability — because the patentees repeatedly told the PTO that the mannitol/EDTA stability discoveries "only made in the context of an aqueous formulation … having a pH of 4–6." (D. Del. brief.) If that construction holds, the stability limitation imports a pH 4–6 requirement, which the prior art must then be shown to render obvious.

3. The prior‑art references of record (from the patent's Prior Art section)

Primary "compound + formulation" reference (the closest art):

• US 5,202,333 (Syntex; "Berger '333") — cited on the page as US5202333A, "Tricyclic 5‑HT3 receptor antagonists." Discloses palonosetron (RS‑25259) and, in Example 13, a representative IV formulation: palonosetron HCl 10–100 mg, dextrose monohydrate q.s. isotonic, citric acid monohydrate 1.05 mg, NaOH 0.18 mg, WFJ to 1 mL, pH 3.7. The '219 specification itself concedes this reference and criticizes its poor shelf stability.

Use/indication references:

• WO 2004/045615 A1 (Helsinn) — palonosetron for treating chemotherapy‑induced emesis.
• WO 2004/073714 A1 (Helsinn) — palonosetron for PONV.
• WO 2003/100091 A1 (Epidauros) — "setrons."

Pharmacology / potency references:

• Eglen et al., Br. J. Pharmacol. 114:860–866 (1995) (also Eglen 1996) — RS‑25259‑197 characterization (extraordinary potency).
• R.D. Clark et al., J. Med. Chem. 36:2645–57 (1993); Gaster & King (1997); Israili (2001); Adis R&D Profile (1999); G. Stacher (2002) — 5‑HT₃ antagonist class knowledge.

Formulation‑science references (the "known solutions"):

• Handbook of Pharmaceutical Excipients, 3d ed. (2000), pp. 140–143, 191–194, 324 et seq. (mannitol); and 6th ed. (2009), pp. 247–250.
• DeLuca et al., "Formulation of Small Volume Parenterals," in Pharmaceutical Dosage Forms: Parenteral Medications, vol. 1, ch. 5, pp. 173–248 (2d ed. 1992).
• Akers, "Excipient–Drug Interactions in Parenteral Formulations," J. Pharm. Sci. 91(11):2283–2300 (2002).
• J. Wells, Pharmaceutical Preformulation, ch. 5 "Drug Stability" (1988); Connors et al., Chemical Stability of Pharmaceuticals (2d ed. 1986).
• Broadhead, "Parenteral Dosage Forms," in Pharmaceutical Preformulation and Formulation, ch. 9, pp. 331–354 (2001) — teaches tonicifier selection (NaCl or dextrose preferred).
• Trissel, Handbook on Injectable Drugs (7th ed. 1992) — injectable pH/solubility/stability compendium.
• Mayron et al., "Stability and compatibility of granisetron HCl in i.v. solutions and oral liquids," Am. J. Health‑Syst. Pharm. 53:294–304 (1996).

Prior‑art setron commercial formulations (the "copy the class" references):

• Ondansetron: US 5,854,270, US 5,955,488, US 6,063,802 (Glaxo).
• Granisetron: US 4,886,808, US 4,937,247, US 5,034,398, US 6,294,548; and US 2001/0020029 A1 (multidose vial formulations).
• General aqueous/tonicity/chelation art: US 5,272,137 (McNeil‑PPC), US 6,132,758 (Schering), US 6,284,749 (Alcon).

The pivotal degradation reference:

• Won et al., "Photolytic and oxidative degradation of an antiemetic agent, RG 12915," Int'l J. Pharmaceutics 121:95–105 (1995) — oxidative degradation of a 5‑HT₃ antagonist and stabilization against it, including chelating‑agent teaching.

Dose/clinical art:

• Macciocchi et al., ASCO 2002, Abstract 1480 (Phase II dose‑ranging, IV palonosetron for highly emetogenic CINV);
• Aapro 2003; Gralla 2003; Eisenberg 2004; Cartmell 2003; Grunberg 2002 (0.25 mg / CINV);
• Phase II Study 2330 Final Report (1995) and the June 2002 MASCC presentation of PALO‑99‑04.

4. The obviousness combinations

The trial record (Teva's expert, Dr. Schonëich, and the DRL petitions) actually framed the theory as "regardless of the starting point, the result follows." Reduced to specific combinations:

Combination 1 — "Known drug, known dosage form": Berger '333 + setron product labels + DeLuca/Handbook/Broadhead + Eglen/Tang

• Berger '333 supplies palonosetron, its IV use for emesis, and a working aqueous IV formulation (a pharmaceutically acceptable carrier, a tonicifier, and an acid/buffer).
• Eglen 1995 / Tang 1998 / the Phase II 2330 data supply the low, single‑IV‑bolus dosing concept (palonosetron being "an order of magnitude more potent," with a ~40‑h half‑life — recited in the '219 background itself).
• The ondansetron/granisetron labels supply the template for a commercial setron IV solution: active drug + acidic pH buffer + tonicifier (NaCl, dextrose, or mannitol) + stabilizer (as Dr. Schonëich put it, "a person of ordinary skill in the art would have made a solution of palonosetron using the same components suggested by the prior art setron drug formulations"). (PTAB petition 1458462.)
• DeLuca/Akers/Handbook supply the routine tools of small‑volume parenteral design (make it isotonic, buffer to a stability‑optimal pH, use a unit‑dose vial).

Motivation: the same class, same indication, same route, same manufacturing platform (aqueous vial) — the paradigmatic "use of a known technique to improve a similar device in the same way" rationale (KSR). The POSITA had every incentive to port the setron formulation template onto palonosetron.

Combination 2 — Chelator: Berger '333 + Won + Castillo + Akers

• Won (1995) shows a structurally related 5‑HT₃ antagonist undergoing oxidative degradation and teaches chelating agents/EDTA as the fix. Palonosetron's tertiary amine makes it a recognizably oxidation‑prone substrate; Akers (2002) reinforces chelator use to mitigate metal‑catalyzed oxidation. The claims' EDTA 0.005–1.0 mg/mL (and claim 2's 0.5 mg/mL) are within the routine stabilizing range.

Motivation: "simple substitution of a known element (EDTA) for a known purpose (antioxidant stabilization) to obtain a predictable result." This maps directly onto claim 1's EDTA limitation and claim 2.

Combination 3 — Tonicifier: Berger '333 (dextrose) + Handbook of Pharmaceutical Excipients (mannitol) + setron labels

• Berger's Example 13 used dextrose as the tonicifier; ondansetron/granisetron injectables used NaCl; the Handbook lists mannitol as a standard isotonicity agent. The claimed mannitol 10–80 mg/mL (claim 3: 41.5 mg/mL ≈ 4.15% w/v, isotonic) is squarely the textbook value.

Motivation: KSR "simple substitution" — replacing one known tonicifier with another known tonicifier, each yielding the same predictable technical effect (isotonicity). The '219 specification itself concedes mannitol at 41.5 mg/mL acts only as a tonicifying agent, not a sweetener (>100 mg/mL would be needed).

Combination 4 — Buffer/pH: Berger '333 + Barton "Citrate Buffer Calculation" + standard buffer art + claim construction

• Berger's formulation was acidified with citric acid; "Barton (Citrate Buffer Calculation), 2000" and the general art teach that citrate is the buffer of choice in the pH 3–6 window (pKa proximity). If the court's pH‑limiting construction of "stable at 24 months" (pH 4–6) applies, then pH 4–6/5.0 and 10–100 mM (20 mM) citrate are routine buffer selections.

Motivation: the class art (ondansetron/granisetron injectables at slightly acidic pH) plus Berger's own citric‑acid example plus the standard "buffer near the pKa" heuristic (cited in DRL's petition) supplies the motivation to buffer palonosetron at pH 4–6. This maps onto claims 4–6.

Combination 5 — Dose: Phase II/Phase III clinical art + Eglen + WO 2004/045615

• The 2330 Final Report (1995), the 1998 Helsinn clinical meeting (doses 0.25/0.75/2.0 mg in a 5 mL solution), and the June 2002 MASCC/PALO‑99‑04 disclosure all place 0.25 mg in 5 mL (0.05 mg/mL) in the public domain of the art. A POSITA optimizing for a single IV bolus would select a unit dose giving 0.05 mg/mL in a 5 mL vial.

Motivation: "obvious to try" across a finite, identified set of clinically supported doses, with a reasonable expectation of reduced side effects at the lowest effective dose (a rationale Teva's Dr. Fruehauf articulated: ".25 milligram … the inflexion point … you want to avoid higher doses … as you go up on doses, you're more likely to get side effects").

Combination 6 — Dependent‑claim optimizations (claims 2, 3, 5, 6, 7)

EDTA 0.5 mg/mL, mannitol 41.5 mg/mL, 20 mM citrate, pH 5.0 ± 0.5, and their combination are, on this theory, the predictable output of routine concentration optimization — the "finite number of identified, predictable solutions" scenario of KSR. Claim 8 (18 months) is a fortiori obvious relative to claim 1 (24 months).

5. Why the motivation‑to‑combine case is strong yet lost

The case for obviousness rests on the classic KSR rationales: (A) combining known elements by known methods; (B) substituting known elements; (C) applying a known technique to a similar compound; and (E) obvious‑to‑try across a small, enumerated design space. On paper, every element of claim 1 is individually known:

palonosetron (Berger '333) + IV/aqueous/isotonic/vial (DeLuca, Handbook) + EDTA (Won) + mannitol (Handbook) + acidic buffer (Berger, Barton) + a clinically disclosed 0.25 mg/5 mL dose (2330, MASCC).

The case against — which the district court credited — is where a § 103 challenge would actually be won or lost:

1. Unexpected results / criticality. The '219's own Examples assert (i) pH 5.0 is uniquely stable (Example 1: stability measured at pH 2.0/5.0/7.4/10.0 at 80 °C); (ii) the lowest palonosetron concentration is most stable (Example 2) — counter‑intuitive versus Berger's 10–100 mg/mL teaching; and (iii) mannitol markedly outperformed sodium chloride as tonicifier (Example 3). The patentees repeatedly told the PTO these findings were "interdependent … a series of building blocks," each conditioned on pH 4–6. That interdependence is the unexpected‑result argument.
2. Teaching away. Broadhead (2001) — a reference on the page — teaches that a tonicifier other than sodium chloride or dextrose should be used only "if the addition of sodium chloride is likely to have an adverse effect." That affirmatively steers away from the claimed mannitol, and the record notes "no reported issues with the use of dextrose" in Berger Example 13.
3. No chelation motivation. The Markman record shows the POSITA would have viewed Berger's citric acid as "nothing else than being a buffer," i.e., Berger "would not have taught a POSA that a chelating agent should be used in any palonosetron formulation" (PTAB petition 1458462).
4. Dose selection was not routine. The district court expressly found it "would not have been obvious … to have selected 0.25mg as a dose, or to arrive at a concentration of 0.05 mg/mL using routine experimentation."
5. Secondary considerations. The court found commercial success (Aloxi®) and long‑felt need favored non‑obviousness (Robbins Kaplan summary).

Net effect: the combination theory is prima facie plausible and follows the KSR playbook, but it confronts genuine (if contestable) evidence of unexpected results, teaching away, and secondary considerations — and the trial court resolved the Graham factors for the patentee. On appeal the Federal Circuit reversed on § 102 and never reached § 103, so the district court's non‑obviousness finding was never overruled; it simply became moot.

6. Claim‑by‑claim vulnerability (record‑based)

7. Bottom line

• Strongest § 103 theory: Berger '333 (US 5,202,333) as the base — it discloses palonosetron, its IV emesis use, and an aqueous IV formulation with a tonicifier and citric acid — combined with (i) the prior‑art setron injectable labels / Glaxo ondansetron & Beecham–Roche granisetron formulation patents as the template; (ii) Won et al. (1995) for the EDTA/oxidation‑stabilization teaching; (iii) the Handbook of Pharmaceutical Excipients and DeLuca/Akers/Broadhead for isotonicity, unit‑dose vials, and tonicifier/buffer selection; and (iv) the Phase II/ASCO/PALO‑99‑04 clinical disclosures for the 0.25 mg/5 mL dose. Dependent claims 2–7 fall to routine optimization; claim 8 falls to claim 1.
• Why it did not carry the day: the fact‑finder found no motivation to select the 0.25 mg dose, credited unexpected results (pH 5.0 criticality; lowest concentration most stable; mannitol > NaCl), teaching away (Broadhead; Berger's dextrose), and secondary considerations (commercial success, long‑felt need). The PTAB never reached § 103 on this patent (PGR2014‑00010 was § 112‑only and settled pre‑institution).
• Decisive caveats to carry forward: (1) the '219's asserted claims were invalidated on the § 102(a)(1) on‑sale bar (Fed. Cir. 2017; aff'd 2019) — a different statutory ground that moots the § 103 fight; and (2) the patent expired 2024‑01‑30, so no prospective infringement exposure exists. Any renewed § 103 attack would also have to reckon with the claim‑construction question flagged in § 2 above — whether "stable at 24[18] months" imports a pH 4–6 requirement (a construction that, if adopted, both narrows the claim and sharpens the prior‑art pH teaching required).

Uncertainty I cannot resolve here: the applicable statutory regime (pre‑AIA § 102(b) vs. AIA § 102(a)(1)) for the published‑art analysis is inconsistent as between the district court's footnote and the patent's post‑AIA status; and the exact reference set DRL/Teva relied on for the '219 specifically (as opposed to the '724/'725/'424/'094 siblings) is scattered across the consolidated record, so the combination above is assembled from the family‑wide obviousness theory as it appears in the petitions and opinion rather than from a single '219‑specific invalidity contention.